Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Telo Genomics Grants Stock Options

Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces the grant of stock options (the "Options") pursuant to its stock option plan to purchase up to an aggregate of 3,300,000 common shares of the Company, subject to TSX Venture Exchange approval, of which 2,500,000 Options were granted to directors and officers, 600,000 Options to employees, and 200,000 Options to consultants of the Company. The Options are exercisable at a price of $0.055 per share and expire five years from the date of grant.